Method of treatment using bisphosphonic acid

Abstract

The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficacious daily dose of a bisphosphonic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients thereof and administering the dose at a period of one two or three consecutive days per month.

1 . A method for treating or inhibiting osteoporosis comprising orally administering to a subject in need of such treatment, once monthly over a period of two consecutive days, about 50 mg to about 250 mg of a bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to from about 50 mg to about 250 mg of said bisphosphonic acid.  
   
   
       2 . The method according to  claim 1  comprising orally administering to a subject in need of such treatment, once monthly over a period of two consecutive days, about 100 mg to about 150 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to about 100 mg to about 150 mg of said bisphosphonic acid.  
   
   
       3 . The method according to  claim 2 , comprising orally administering to a subject in need of such treatment, once monthly over a period of two consecutive days, about 100 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to about 100 mg of bisphosphonic acid.  
   
   
       4 . The method according to  claim 2 , comprising orally administering to a subject in need of such treatment, once monthly over a period of two consecutive days, about 150 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to about 150 mg of bisphosphonic acid.  
   
   
       5 . The method of  claim 2  comprising orally administering to a subject in need of such treatment, once monthly over a period of two consecutive days, 100 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to 100 mg of bisphosphonic acid.  
   
   
       6 . The method of  claim 2  comprising orally administering to a subject in need of such treatment, once monthly over a period of two consecutive days, 150 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to 150 mg of bisphosphonic acid.  
   
   
       7 . The method of  claim 1  wherein said bisphosphonic acid is risedronic acid.  
   
   
       8 . The method of  claim 2  wherein said bisphosphonic acid is risedronic acid.  
   
   
       9 . The method of  claim 3  wherein said bisphosphonic acid is risedronic acid.  
   
   
       10 . The method of  claim 4  wherein said bisphosphonic acid is risedronic acid.  
   
   
       11 . The method of  claim 6  wherein said bisphosphonic acid is risedronic acid.  
   
   
       12 . The method of  claim 2  wherein said bisphosphonic acid is administered in the form of a solid pharmaceutical composition.  
   
   
       13 . The method of  claim 4  wherein said bisphosphonic acid is administered in the form of a solid pharmaceutical composition.  
   
   
       14 . The method of  claim 6  wherein said bisphosphonic acid is administered in the form of a solid pharmaceutical composition.  
   
   
       15 . The method of  claim 8  wherein said risedronic acid is administered in the form of a solid pharmaceutical composition.  
   
   
       16 . The method of  claim 10  wherein said risedronic acid is administered in the form of a solid pharmaceutical composition.  
   
   
       17 . The method of  claim 11  wherein said risedronic acid is administered in the form of a solid pharmaceutical composition.